During the past decade, Centre hospitalier regional de Trois-Rivieres conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 10 clinical trials were completed, i.e. on average, 142.9% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 6 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre hospitalier regional de Trois-Rivieres" #1 sponsor was "Canadian Cancer Trials Group" with 4 trials, followed by "Sir Mortimer B. Davis - Jewish General Hospital" with 3 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Bio-K Plus International Inc." with 1 trials sponsored and "Brigham and Women's Hospital" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre hospitalier regional de Trois-Rivieres" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Albany Stratton VA Medical Center" with 1 trials as a collaborator, "Australian and New Zealand Urogenital and Prostate Cancer Trials Group" with 1 trials as a collaborator and "Boston VA Research Institute, Inc." with 1 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "Centre hospitalier regional de Trois-Rivieres" are "Prostate Cancer" (3 trials), "Clostridium Infections" (2 trials), "Acute Coronary Syndrome" (1 trials), "Brain and Central Nervous System Tumors" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Centre hospitalier regional de Trois-Rivieres" in a lesser frequency.

Most popular intervention types in "Centre hospitalier regional de Trois-Rivieres" are "Drug" (11 trials), "Radiation" (5 trials), "Other" (3 trials), "Biological" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Best Supportive Care" (3 trials), "Paclitaxel" (2 trials), "Placebo" (2 trials), "Androgen deprivation therapy" (1 trials) and "BBI608" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre hospitalier regional de Trois-Rivieres" are 13 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Centre hospitalier regional de Trois-Rivieres". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Centre hospitalier regional de Trois-Rivieres, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre hospitalier regional de Trois-Rivieres, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".